NexMed Inc, a developer of innovative topical treatments based on its NexACT drug delivery technology, has received U.S. Patent 6,414,028 for its application entitled, "Topical Compositions Containing Prostaglandin E1". This patent covers new and optimized topical formulations of prostaglandin E1 (alprostadil). Alprox-TD is NexMed's proprietary cream treatment for erectile dysfunction (ED) and incorporates prostaglandin E1 with the NexACT platform technology.
Dr. James Yeager, Senior Vice President for Scientific Affairs commented, "With the issuance of this new patent, our U.S. protection for Alprox-TD is expanded to seven issued patents, which includes comprehensive coverage for the product's formulation, method of delivery and packaging." Dr. Yeager added, "We have additional U.S. patent applications pending, which if issued, would further strengthen the patent position for Alprox-TD. We also have filed corresponding foreign applications to solidify our global patent protection for Alprox-TD."
In the U.S., NexMed is conducting two Phase 3 pivotal safety and efficacy studies and 1 open-label safety study for Alprox-TD. The ongoing clinical trials will enroll up to 2,500 patients with mild to severe ED. Internationally, Alprox-TD has been selling in China and Hong Kong under the Befar trademark and is the first approved commercial topical ED treatment anywhere in the world.